• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression therapy treatment for depression

Traditional therapies and medications are not effective for a lot of patients suffering from depression. A customized natural treatment for depression could be the solution.

Cue is an intervention platform that transforms sensor data collected from smartphones into personalized micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to determine their feature predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet only half of those suffering from the condition receive treatment. To improve outcomes, clinicians must be able identify and treat patients who are the most likely to benefit from certain treatments.

Personalized depression treatment is one method of doing this. By using mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from which treatments. Two grants were awarded that total more than $10 million, they will make use of these tools to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

So far, the majority of research on predictors for depression treatment effectiveness has centered on clinical and sociodemographic characteristics. These include demographics like age, gender, and education, as well as clinical aspects such as symptom severity and comorbidities as well as biological markers.

Few studies have used longitudinal data in order to determine mood among individuals. A few studies also consider the fact that mood can be very different between individuals. Therefore, it is critical to create methods that allow the determination of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to detect patterns of behaviour and emotions that are unique to each person.

The team also devised a machine-learning algorithm that can create dynamic predictors for each person's depression mood. The algorithm combines these personal differences into a unique "digital phenotype" for each participant.

This digital phenotype was correlated with CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was weak however (Pearson r = 0,08; P-value adjusted by BH 3.55 x 10 03) and varied greatly among individuals.

Predictors of symptoms

depression Treatment medications (glamorouslengths.com) is among the world's leading causes of disability1 but is often not properly diagnosed and treated. Depressive disorders are often not treated due to the stigma associated with them and the lack of effective treatments.

To allow for individualized treatment, identifying patterns that can predict symptoms is essential. The current prediction methods rely heavily on clinical interviews, which are unreliable and only detect a few features associated with depression.

Using machine learning to blend continuous digital behavioral phenotypes that are captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, CAT-DI) with other predictors of symptom severity can improve diagnostic accuracy and increase treatment efficacy for depression. Digital phenotypes can provide continuous, high-resolution measurements as well as capture a wide range of unique behaviors and activity patterns that are difficult to record through interviews.

The study involved University of California Los Angeles (UCLA) students experiencing mild to severe depression symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online assistance or in-person clinics in accordance with their severity of depression. Those with a score on the CAT-DI of 35 65 were assigned online support via the help of a coach. Those with scores of 75 were routed to clinics in-person for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their demographics and psychosocial characteristics. The questions included age, sex and education and marital status, financial status and whether they were divorced or not, the frequency of suicidal ideas, intent or attempts, and how often they drank. The CAT-DI was used to assess the severity of depression symptoms on a scale from 100 to. The CAT-DI tests were conducted every week for those that received online support, and once a week for those receiving in-person care.

Predictors of Treatment Reaction

A customized treatment for depression is currently a research priority and a lot of studies are aimed at identifying predictors that help clinicians determine the most effective medications for each patient. Pharmacogenetics, for instance, is a method of identifying genetic variations that affect how the body's metabolism reacts to drugs. This lets doctors choose the medications that are likely to be the most effective for each patient, reducing time and effort spent on trial-and error treatments and eliminating any adverse effects.

Another promising approach is building prediction models using multiple data sources, including data from clinical studies and neural imaging data. These models can then be used to determine the most appropriate combination of variables that are predictive of a particular outcome, such as whether or not a drug is likely to improve the mood and symptoms. These models can also be used to predict the response of a patient to treatment that is already in place, allowing doctors to maximize the effectiveness of current treatment.

A new generation of machines employs machine learning techniques such as supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and improve predictive accuracy. These models have been demonstrated to be effective in predicting treatment outcomes for example, the response to antidepressants. These methods are becoming popular in psychiatry, and it is likely that they will become the norm for the future of clinical practice.

Research into the underlying causes of depression continues, as do predictive models based on ML. Recent findings suggest that depression is linked to the malfunctions of certain neural networks. This suggests that an individualized depression treatment will be focused on therapies that target these circuits in order to restore normal functioning.

Internet-delivered interventions can be an effective method to achieve this. They can offer an individualized and tailored experience for patients. A study showed that a web-based program improved symptoms and provided a better quality of life for MDD patients. Furthermore, a randomized controlled trial of a personalized approach to treating extreme depression treatment showed sustained improvement and reduced adverse effects in a large percentage of participants.

Predictors of side effects

A major obstacle in individualized depression treatment involves identifying and predicting which antidepressant medications will have very little or no side effects. Many patients are prescribed a variety of drugs before they find a drug that is safe and effective. Pharmacogenetics provides an exciting new method for an efficient and specific approach to choosing antidepressant medications.

There are several predictors that can be used to determine which antidepressant should be prescribed, such as gene variations, phenotypes of patients such as gender or ethnicity, and the presence of comorbidities. However finding the most reliable and valid predictors for a particular treatment is likely to require randomized controlled trials with considerably larger samples than those that are typically part of clinical trials. This is because it could be more difficult to identify interactions or moderators in trials that contain only one episode per person rather than multiple episodes over a long period of time.

Furthermore the prediction of a patient's reaction to a particular medication is likely to require information on symptoms and comorbidities and the patient's prior subjective experience with tolerability and efficacy. There are currently only a few easily assessable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

Many issues remain to be resolved in the use of pharmacogenetics to treat depression. First, a clear understanding of the genetic mechanisms is required as well as a clear definition of what is a reliable indicator of treatment response. Additionally, ethical issues such as privacy and the ethical use of personal genetic information, must be carefully considered. In the long run the use of pharmacogenetics could provide an opportunity to reduce the stigma associated with mental health treatment and improve treatment outcomes ect for treatment resistant depression those struggling with depression. But, like any approach to psychiatry careful consideration and implementation is essential. The best course of action is to offer patients a variety of effective depression medication options and encourage them to talk openly with their doctors about their experiences and concerns.